Lapatinib not only inhibited HER2 phosphorylation, but also decreased HER2 receptor ubiquitination and increased the accumulation of inactive HER2 receptors at the cell surface, according to recent in vitro work using HER2-overexpressing breast cancer cell lines (SKBR3 and MCF7-HER2) and correlation with in vivo data using BT474 xenografts [19]. This evidence concerns the gene ERBB2 and breast carcinoma.